We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+8.78%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.38B
AUM Growth
-$236M
Cap. Flow
-$330M
Cap. Flow %
-23.99%
Top 10 Hldgs %
54.43%
Holding
96
New
13
Increased
16
Reduced
18
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$22.4M
3
BDX icon
Becton Dickinson
BDX
+$21.2M
4
BBIO icon
BridgeBio Pharma
BBIO
+$20.8M
5
OM icon
Outset Medical
OM
+$20.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$25.6M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$22.8M
3
IJH icon
iShares Core S&P Mid-Cap ETF
IJH
+$21.7M
4
LLY icon
Eli Lilly
LLY
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OM icon
26
Outset Medical
OM
$96.8M
$18.6M 1.35%
+1,685,727
New +$20.1M
HUM icon
27
Humana
HUM
$43.5B
$16.7M 1.21%
63,238
-19,799
-24% -$5.35M
SNDX icon
28
Syndax Pharmaceuticals
SNDX
$1.69B
$11.4M 0.83%
926,424
+719,553
+348% +$10.1M
OSCR icon
29
Oscar Health
OSCR
$9.16B
$11.3M 0.82%
860,821
– –
INDV icon
30
Indivior Pharmaceuticals
INDV
$4.31B
$11.1M 0.8%
+1,159,833
New +$12.2M
AZN icon
31
AstraZeneca
AZN
$241B
$11M 0.8%
+75,100
New +$10.9M
TMO icon
32
Thermo Fisher Scientific
TMO
$209B
$10.9M 0.79%
21,897
+857
+4% +$464K
XRT icon
33
CALL
State Street SPDR S&P Retail ETF
XRT
$332M
$10.9M 0.79%
+157,200
New +$11.9M
CNC icon
34
Centene
CNC
$31.7B
$8.22M 0.6%
135,398
-9,103
-6% -$550K
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
$8.2M 0.6%
570,546
+198,780
+53% +$3.25M
ICLR icon
36
Icon
ICLR
$12.1B
$7.18M 0.52%
41,038
-87,599
-68% -$17M
QURE icon
37
uniQure
QURE
$3.03B
$6.36M 0.46%
599,967
+316,809
+112% +$4.44M
INBX icon
38
Inhibrx
INBX
$1.23B
$6.15M 0.45%
439,283
+303,737
+224% +$4.12M
PRAX icon
39
Praxis Precision Medicines
PRAX
$8.64B
$6.09M 0.44%
160,866
+41,357
+35% +$2.58M
NEO icon
40
NeoGenomics
NEO
$2.09B
$5.56M 0.4%
+585,381
New +$7.31M
ERAS icon
41
Erasca
ERAS
$6.38B
$4.78M 0.35%
3,489,559
-900,868
-21% -$1.55M
BHVN icon
42
Biohaven
BHVN
$2.07B
$4.74M 0.34%
197,307
-234,609
-54% -$8.27M
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$4.11M 0.3%
46,453
+3,613
+8% +$352K
PMVP icon
44
PMV Pharmaceuticals
PMVP
$62.4M
$3.6M 0.26%
3,301,942
+1,222,697
+59% +$1.66M
SRPT icon
45
Sarepta Therapeutics
SRPT
$1.73B
$3.24M 0.24%
50,809
-49,363
-49% -$5.2M
XENE icon
46
Xenon Pharmaceuticals
XENE
$6.19B
$3.09M 0.22%
92,236
-24,762
-21% -$940K
AMLX icon
47
Amylyx Pharmaceuticals
AMLX
$2.43B
$2.95M 0.21%
+834,135
New +$2.97M
IOBT
48
DELISTED
IO Biotech
IOBT
$2.55M 0.19%
2,341,107
– –
XRT icon
49
State Street SPDR S&P Retail ETF
XRT
$332M
$2.52M 0.18%
+36,471
New +$2.75M
HOWL icon
50
Werewolf Therapeutics
HOWL
$20.1M
$2.44M 0.18%
2,506,520
-398,945
-14% -$522K
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q1 2025 Portfolio in Review

As of Q1 2025, PFM Health Sciences held 96 positions worth $1.38B, down 15% from $1.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

PFM Health Sciences withdrew a net $330M in Q1 2025, closing 30 positions and reducing 18 holdings. Its most notable exit was DexCom, an estimated $25.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 75% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Elevance Health worth $38.4M.

  • PFM Health Sciences's largest Q1 2025 buy was Elevance Health: 88,222 shares worth $38.4M.
  • PFM Health Sciences added most to BridgeBio Pharma in Q1 2025, an estimated $20.8M increase.
  • PFM Health Sciences's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $20.7M.
  • PFM Health Sciences fully exited DexCom in Q1 2025, selling an estimated $25.6M.
  • PFM Health Sciences's ten largest holdings make up 54% of its $1.38B portfolio in Q1 2025.
  • PFM Health Sciences opened 13 new positions and closed 30 in Q1 2025.
  • PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $1.38B.

Based on PFM Health Sciences's 13F filing for Q1 2025, filed 15 May 2025.